Evolent Health, Inc. (EVH)
NYSE: EVH · Real-Time Price · USD
3.950
+0.050 (1.28%)
May 29, 2026, 4:00 PM EDT - Market closed
Evolent Health Stock Forecast
Stock Price Forecast
According to 16 analysts polled by S&P Global, Evolent Health stock has a consensus rating of "Buy" and an average price target of $5.75. The average 1-year stock price forecast is 45.57% higher than the current stock price, while the lowest is $3.00 (-24.05%) and the highest is $8.00 (+102.53%).
Price Target: $5.75 (+45.57%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Evolent Health stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 10 | 10 | 10 | 10 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 1 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 16 | 16 | 16 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 15, 2026 |
| Citi | Citi | Buy Maintains $4 → $5.5 | Buy | Maintains | $4 → $5.5 | +39.24% | May 15, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $5 → $6 | Buy | Maintains | $5 → $6 | +51.90% | May 12, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $7 → $8 | Buy | Maintains | $7 → $8 | +102.53% | May 11, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 8, 2026 |
Financial Forecast
Revenue This Year
2.52B
from 1.88B
Increased by 34.15%
Revenue Next Year
3.00B
from 2.52B
Increased by 19.11%
EPS This Year
0.15
from -5.07
EPS Next Year
0.39
from 0.15
Increased by 160.45%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | 2.7B | 3.3B | ||||
| Avg | 2.5B | 3.0B | ||||
| Low | 2.4B | 2.8B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | 46.1% | 30.9% | ||||
| Avg | 34.2% | 19.1% | ||||
| Low | 27.1% | 11.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 0.27 | 0.75 | |||
| Avg | 0.15 | 0.39 | |||
| Low | 0.05 | 0.16 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 398.7% | |||
| Avg | - | 160.4% | |||
| Low | - | 4.9% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.